Cost-effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States
This article, published in the journal Pediatrics, discusses a study to evaluate and compare the projected health and economic impact of meningococcal conjugate A/C/Y/W-135 (MCV-4) vaccination of adolescents, toddlers, and infants in the United States. The study measured meningococcal cases and deaths prevented, cost per case prevented, cost per life-year saved, and cost per quality-adjusted life-year saved, and concluded that routine MCV-4 vaccination would reduce the burden of disease in vaccinated cohorts but at a relatively high net societal cost. The projected cost-effectiveness of adolescent vaccination approaches that of recently adopted childhood vaccines under conditions of above-average meningococcal disease incidence or at a lower cost per vaccination.
Author(s): Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team
Visit web page (English)
(Located at pediatrics.aappublications.org)
Citation: Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team. Cost-effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States. Pediatrics. 2005;115(5):1220-1232.